+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031

22 February 2021

Visiongain has published a new report on Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031: Forecasts By Drug Type (Branded Drug, and Generic Drug), By Dosage Form (Capsule, and Suspension), By Indication (Influenza A, Influenza B, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospital, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Tamiflu (Oseltamivir Phosphate) was valued at US$ xx Million in 2020 and is projected to reach a market value of US$ xx Million by 2031. North America dominated the global Tamiflu (Oseltamivir Phosphate) and is projected to witness a CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Tamiflu (Oseltamivir Phosphate)
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Tamiflu (Oseltamivir Phosphate). Different recovery scenarios are also included in the report for all the segments and regions/nations. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Increasing Prevalence of Influenza and Flu
Influenza and flu prevalence has increased very rapidly as compared to the last few years and it is expected that Influenza and flu prevalence will increase during the forecast period. According to the U.S. Department of Health & Human Services that approximately 35.5 million are suffering from influenza. Increasing influenza and flu cases creates a huge demand for the influenza and flu treatment. Due to which increasing prevalence of influenza and flu is working as a driver for the Influenza and flu treatment market.

Rising Investment in Tamiflu (Oseltamivir Phosphate)
There is a very rapid increase in demand of tamiflu (Oseltamivir Phosphate) around the world for the Influenza and flu. Recently, the market has reported a sudden rise in the demand of Tamiflu (Oseltamivir Phosphate) along with increasing regulatory approvals, new investment and growing initiatives. Various manufactures has increased their funding for tamiflu (Oseltamivir Phosphate) and on the other hand many manufacturers have launched their product portfolios in tamiflu (Oseltamivir Phosphate) which have helped to fulfil demand and to work as driver for the market. Rapid surge in the investment is increasing demand of tamiflu (Oseltamivir Phosphate) products due to this reason the factor is working as a driver for the market.

Market Opportunities

Increasing Strategic Initiatives In Retinal Disorders Treatment Drugs
Manufactures present in the market are taking various strategic initiatives in order to increase their revenue generation in the market, Strategic Initiatives such as mergers & acquisitions, product launches and press conference & event. These strategic initiatives are helping manufacturers in the market to increase their revenue generation due to this reason increasing strategic initiatives in tamiflu (Oseltamivir Phosphate) market is creating new opportunities for the Tamiflu (Oseltamivir Phosphate) market.

Competitive Landscape

Top companies (F.Hoffmann-La Roche Ltd., NATCO Pharma Limited, and Teva Pharmaceutical Industries Ltd..) constitute more than XX% share of the global Tamiflu (Oseltamivir Phosphate). Other companies profiled in the report include: LUPIN Limited, Amneal pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Mylan N.V., Hetero GroupSome of the key developments are listed below:

● In 2019, Alembic Pharmaceuticals received the U.S. Food and Drug Administration approval for Oseltamivir phosphate capsules. Oseltamivir phosphate is a generic version of Tamiflu and is designed for the treatment of acute, uncomplicated illness due to influenza A and B infection. The approval will help the company to expand its market portfolio.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033

The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.

03 October 2023


Visiongain Publishes Bioreactors Market Report 2023-2033

The global Bioreactors market was estimated to be valued at US$9,977.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.

29 September 2023


Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.

27 September 2023


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.

25 September 2023